Articles by Arjun Seth, MD
The discussion explores the evolving management of myasthenia gravis (MG), focusing on treatment selection, sequencing, and strategies for switching therapies in clinical practice. The expert faculty highlight how the expanding range of targeted therapies, including FcRn inhibitors, complement inhibitors, and B-cell–depleting agents, has enabled more individualized, patient-centered care, balancing short-term symptom control with long-term disease management. The panelists emphasize a shift toward earlier, proactive optimization of therapy to improve long-term outcomes and reduce disease burden in patients with MG.
The discussion explores the evolving management of myasthenia gravis (MG), focusing on treatment selection, sequencing, and strategies for switching therapies in clinical practice. The expert faculty highlight how the expanding range of targeted therapies, including FcRn inhibitors, complement inhibitors, and B-cell–depleting agents, has enabled more individualized, patient-centered care, balancing short-term symptom control with long-term disease management. The panelists emphasize a shift toward earlier, proactive optimization of therapy to improve long-term outcomes and reduce disease burden in patients with MG.
Ali Habib, MD, and Arjun Seth, MD, discuss how B-cell–targeted therapies represent a promising upstream treatment approach for myasthenia gravis that could provide more sustained efficacy compared with current downstream treatments like complement inhibitors and FcRn antagonists, with CD19-targeting agents like inebilizumab showing particular promise in clinical trials for both acetylcholine receptor and MuSK antibody subtypes.
Ali Habib, MD, and Arjun Seth, MD, discuss how B-cell–targeted therapies represent a promising upstream treatment approach for myasthenia gravis that could provide more sustained efficacy compared with current downstream treatments like complement inhibitors and FcRn antagonists, with CD19-targeting agents like inebilizumab showing particular promise in clinical trials for both acetylcholine receptor and MuSK antibody subtypes.
